OraVescent Fentanyl (OVF) for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

NCT00105937 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
300
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Cephalon